Article
Oncology
Assunta Cirella, Elixabet Bolanos, Claudia Augusta Di Trani, Carlos E. de Andrea, Sandra Sanchez-Gregorio, Inaki Etxeberria, Jose Gonzalez-Gomariz, Irene Olivera, Davide Brocco, Javier Glez-Vaz, Carlos Luri-Rey, Arantza Azpilikueta, Inmaculada Rodriguez, Myriam Fernandez-Sendin, Josune Egea, Inaki Eguren, Miguel F. Sanmamed, Belen Palencia, Alvaro Teijeira, Pedro Berraondo, Ignacio Melero
Summary: IL12 and IL18 combination therapy can enhance antitumor effects. Intratumoral administration of DR-18 construct can avoid systemic toxicity and improve therapeutic efficiency.
CANCER IMMUNOLOGY RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Andrei Slabodkin, Maria Chernigovskaya, Ivana Mikocziova, Rahmad Akbar, Lonneke Scheffer, Milena Pavlovic, Habib Bashour, Igor Snapkov, Brij Bhushan Mehta, Cedric R. Weber, Jose Gutierrez-Marcos, Ludvig M. Sollid, Ingrid Hobaek Haff, Geir Kjetil Sandve, Philippe A. Robert, Victor Greiff
Summary: A study found that VDJ recombination rules may differ between individuals, leading to variations in the probability of generating (auto)antigen-specific Ig sequences. In addition to genetic factors, VDJ recombination is also influenced by non-genetic modulation.
Article
Engineering, Environmental
Xue-Ming Cao, Li-Hua Li, Hong-Zhi Liang, Jia-Dong Li, Zi-Jian Chen, Lin Luo, Yi-Na Lu, Yu-Xin Zhong, Yu-Dong Shen, Hong-Tao Lei, Hong Wang, Zhen-Lin Xu
Summary: A specific antibody for BA was generated and a dual-modular immunosensor was established for the detection of BA in food. The immunosensor showed good sensitivity and reproducibility, with a limit of detection below 10 ng/mL and consistent results with standard LC-MS/MS.
JOURNAL OF HAZARDOUS MATERIALS
(2023)
Article
Multidisciplinary Sciences
Masaru Takeshita, Hidehiro Fukuyama, Katsuhiko Kamada, Takehisa Matsumoto, Chieko Makino-Okamura, Qingshun Lin, Machie Sakuma, Eiki Kawahara, Isato Yamazaki, Tomomi Uchikubo-Kamo, Yuri Tomabechi, Kazuharu Hanada, Tamao Hisano, Saya Moriyama, Yoshimasa Takahashi, Mutsumi Ito, Masaki Imai, Tadashi Maemura, Yuri Furusawa, Seiya Yamayoshi, Yoshihiro Kawaoka, Mikako Shirouzu, Makoto Ishii, Hideyuki Saya, Yasushi Kondo, Yuko Kaneko, Katsuya Suzuki, Koichi Fukunaga, Tsutomu Takeuchi
Summary: We generated broadly neutralizing antibodies from convalescent B cells targeting both the Wuhan strain and the Gamma variant. These antibodies neutralized all strains prior to the Omicron variant and some Omicron substrains. Structural analysis revealed distinctive binding modes including ACE2 mimicry. In an animal model, a representative antibody showed dose-dependent reduction of lung viral titer even at a low dose of 2 mg/kg, indicating the therapeutic potential of these antibodies and the importance of initial cell-screening strategy.
Article
Multidisciplinary Sciences
Ellen Young, Boyd Yount, Petraleigh Pantoja, Sandra Henein, Rita M. Meganck, Jennifer McBride, Jennifer E. Munt, Thomas J. Baric, Deanna Zhu, Trevor Scobey, Stephanie Dong, Longping V. Tse, Melween I. Martinez, Armando G. Burgos, Rachel L. Graham, Laura White, Aravinda DeSilva, Carlos A. Sariol, Ralph S. Baric
Summary: The four dengue virus serotypes circulate globally and cause significant human disease. Current dengue vaccines induce balanced protective immunity. By employing chimeric viruses, researchers have successfully developed a live chimeric DENV2/4 EDII virus that replicates efficiently in primates and elicits neutralizing antibodies for both DENV2 and DENV4, providing a simplified vaccine strategy.
NATURE COMMUNICATIONS
(2023)
Article
Chemistry, Medicinal
Tianyu Wang, Kaizhen Wang, Yu Zhang, Kuojun Zhang, Shi Cai, Sheng Jiang, Yibei Xiao, Xiangyu Zhang
Summary: Researchers have discovered a novel immune checkpoint called VISTA and developed bifunctional inhibitors to target it. These inhibitors effectively reverse VISTA-mediated immunosuppression and enhance the anti-tumor activity of immune cells. This discovery offers a new approach for cancer immunotherapy.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Biochemical Research Methods
Mareile Boschanski, Tobias Krueger, Lennard Karsten, Georg Falck, Sarfaraz Alam, Marcus Gerlach, Benjamin Mueller, Kristian M. Mueller, Norbert Sewald, Thomas Dierks
Summary: This study demonstrates an improved and facile strategy for functionalizing DARPin and scFv425-Fc antibodies targeting EGFR, by conjugating them with MMAE and CF for successful testing in cell culture for receptor binding, internalization, and cytotoxicity.
BIOCONJUGATE CHEMISTRY
(2021)
Article
Fisheries
Walissara Jirapongpairoj, Reiko Nozaki, Keiichiro Koiwai, Ikuo Hirono, Hidehiro Kondo
Summary: The structures of fish serum immunoglobulin differ among different fish species. In this study, a rabbit immunoglobulin light chain bound to fish serum immunoglobulin was accidentally isolated using phage display. The binding specificities of the recombinant protein to fish immunoglobulins were analyzed using ELISA and western blotting.
FISH & SHELLFISH IMMUNOLOGY
(2022)
Article
Immunology
Shengli Song, Miriam Manook, Jean Kwun, Annette M. Jackson, Stuart J. Knechtle, Garnett Kelsoe
Summary: Antibody-mediated allograft rejection is a major cause of kidney transplant failure, with research focusing on identifying antibodies and optimizing therapies. New reagents and techniques have been used to measure MHC sensitization and isolate HLA-specific B cells from sensitized patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Mathematical & Computational Biology
Tae Jin Lee, Jose A. Vazquez, Arni S. R. Srinivasa Rao
Summary: Developing broadly neutralizing antibodies and eCD4-Ig as therapeutic alternatives for HIV elimination shows promising results. Research indicates the importance of ADCC effect in antibody design and the balance between ADCC and neutralization effect for HIV elimination. Mathematical modeling helps investigate the relationship between eCD4-Ig levels, ADCC effects, and viral neutralization effect in HIV therapy.
MATHEMATICAL BIOSCIENCES AND ENGINEERING
(2021)
Article
Biochemical Research Methods
Lin Zhang, Zewei Wang, Zhiyuan Wang, Fang Luo, Mingfeng Guan, Meimei Xu, Yundong Li, Yaoyang Zhang, Zhaoyin Wang, Wenyuan Wang
Summary: This study presents a simple method to produce dual payload conjugates, enhancing the functional diversity and therapeutic efficacy of ADCs. By site-specific engineering, the antibodies can sequentially conjugate with two mechanistically distinct cytotoxic drugs. This strategy holds the potential to overcome drug resistance and improve treatment outcomes.
BIOCONJUGATE CHEMISTRY
(2021)
Article
Pharmacology & Pharmacy
Hung-Jun Lin, Tien-Li Liang, Yao-Yuan Chang, Der-Zen Liu, Jia-Yu Fan, Steve R. Roffler, Shyr-Yi Lin
Summary: In this study, an anti-EGFR and anti-fibroblast activation protein bispecific antibody-targeted liposomal irinotecan (BS-LipoIRI) was fabricated to target pancreatic cancer cells and tumor-associated fibroblasts. The drug showed better efficacy in cellular uptake compared to LipoIRI and was able to inhibit pancreatic cancer growth in vivo.
Article
Immunology
Sai Pooja Mahajan, Jeffrey A. Ruffolo, Rahel Frick, Jeffrey J. Gray
Summary: Antibodies are important therapeutics for treating cancer, infectious disease, and inflammation, and their target affinity needs to be improved through engineering. This study proposes the F(v)Hallucinator pipeline based on deep learning to design antibody sequences, resulting in the generation of inexpensive, diverse, and targeted antibody libraries enriched in binders for the target antigen. This provides a new approach for antibody affinity maturation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Carina Lynn Gehlert, Pegah Rahmati, Ammelie Svea Boje, Dorothee Winterberg, Steffen Krohn, Thomas Theocharis, Elisa Cappuzzello, Anja Lux, Falk Nimmerjahn, Ralf J. Ludwig, Marta Lustig, Thies Roesner, Thomas Valerius, Denis Martin Schewe, Christian Kellner, Katja Klausz, Matthias Peipp
Summary: This study engineered a CD19 antibody to enhance effector cell-mediated killing and CDC activity. The dual optimized CD19 antibody showed improved ADCC, ADCP, and CDC compared to the non-engineered antibody. This finding is crucial for improving CD19-directed cancer immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Medicinal
Shuai Zheng, Kuojun Zhang, Xiangyu Zhang, Yibei Xiao, Tianyu Wang, Sheng Jiang
Summary: Blocking PD-1/PD-L1 and CTLA-4 has limited therapeutic effect, so researchers are investigating more targets. VISTA has been identified as an appealing target for immunotherapy in various cancers. Several VISTA inhibitors are currently in clinical and preclinical trials.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)